RayKnowChina Research Map
Shortlist

RecruitingBreast cancerPhase 3

Registered title, quoted from ClinicalTrials.gov

A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer

An open trial on breast cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 52 hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 52

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteAffiliated Cancer Hospital of Xinjiang Medical University新疆医科大学附属肿瘤医院UrumqiHospital page
  2. Study siteAffiliated Hospital of Southwest Medical University西南医科大学附属医院LuzhouHospital page
  3. Study siteAnhui Provincial Cancer Hospital安徽省肿瘤医院HefeiHospital page
  4. Study siteAnyang Tumor Hospital安阳市肿瘤医院AnyangHospital page
  5. Study siteCangzhou Central Hospital沧州市中心医院TianjinHospital page
  6. Study siteChongqing University Cancer Hospital重庆大学附属肿瘤医院ChongqingHospital page
  7. Study siteFirst Affiliated Hospital of Bengbu Medical University蚌埠医学院第一附属医院BengbuHospital page
  8. Study siteFirst Affiliated Hospital of Chongqing Medical University重庆医科大学附属第一医院ChongqingHospital page
  9. Study siteFirst Affiliated Hospital of Guangxi Medical University广西医科大学第一附属医院NanningHospital page
  10. Study siteFirst Affiliated Hospital of Henan University of Science and Technology河南科技大学第一附属医院LuoyangHospital page
  11. Study siteFirst Affiliated Hospital of Jinzhou Medical University锦州医科大学附属第一医院BeijingHospital page
  12. Study siteFirst Affiliated Hospital of Wenzhou Medical University温州医科大学附属第一医院WenzhouHospital page
  13. Study siteFirst Affiliated Hospital of Xi'an Jiaotong University西安交通大学第一附属医院Xi'anHospital page
  14. Study siteFirst Affiliated Hospital of Xinxiang Medical University河南医药大学第一附属医院XinxiangHospital page
  15. Study siteFirst Affiliated Hospital of Zhengzhou University郑州大学第一附属医院ZhengzhouHospital page
  16. Study siteFirst Affiliated Hospital, University of South China南华大学附属第一医院HengyangHospital page
  17. Study siteFirst Hospital of China Medical University中国医科大学附属第一医院ShenyangHospital page
  18. Study siteFirst Hospital of Jilin University吉林大学第一医院ChangchunHospital page
  19. Study siteFirst Hospital of Lanzhou University兰州大学第一医院LanzhouHospital page
  20. Study siteFirst Hospital of Shanxi Medical University山西医科大学第一医院TaiyuanHospital page
  21. Study siteFourth Hospital of Hebei Medical University河北医科大学第四医院ShijiazhuangHospital page
  22. Study siteFudan University Shanghai Cancer Center复旦大学附属肿瘤医院ShanghaiHospital page
  23. Study siteGuangxi Medical University Cancer Hospital广西医科大学附属肿瘤医院NanningHospital page
  24. Study siteGuizhou Provincial People's Hospital贵州省人民医院GuiyangHospital page
  25. Study siteHarbin Medical University Cancer Hospital哈尔滨医科大学附属肿瘤医院HarbinHospital page
  26. Study siteHuashan Hospital复旦大学附属华山医院ShanghaiHospital page
  27. Study siteJiangsu Province Hospital江苏省人民医院(南医大一附院)NanjingHospital page
  28. Study siteJiangxi Cancer Hospital江西省肿瘤医院NanchangHospital page
  29. Study siteLiaoning Cancer Hospital & Institute辽宁省肿瘤医院ShenyangHospital page
  30. Study siteLinyi Cancer Hospital临沂市肿瘤医院LinyiHospital page
  31. Study siteMeizhou People's Hospital梅州市人民医院MeizhouHospital page
  32. Study siteNanjing Drum Tower Hospital南京鼓楼医院NanjingHospital page
  33. Study siteNingbo Medical Center Lihuili Hospital宁波市医疗中心李惠利医院NingboHospital page
  34. Study sitePeking Union Medical College Hospital北京协和医院BeijingHospital page
  35. Study sitePeking University Cancer Hospital北京大学肿瘤医院BeijingHospital page
  36. Study siteSecond Affiliated Hospital of Chongqing Medical University重庆医科大学附属第二医院ChongqingHospital page
  37. Study siteSecond Affiliated Hospital of Fujian Medical University福建医科大学附属第二医院QuanzhouHospital page
  38. Study siteSecond Affiliated Hospital of Guangzhou Medical University广州医科大学附属第二医院GuangzhouHospital page
  39. Study siteSecond Xiangya Hospital中南大学湘雅二医院ChangshaHospital page
  40. Study siteShandong Cancer Hospital and Institute山东省肿瘤医院JinanHospital page
  41. Study siteShantou Central Hospital汕头市中心医院ShantouHospital page
  42. Study siteShanxi Cancer Hospital山西省肿瘤医院TaiyuanHospital page
  43. Study siteShengjing Hospital of China Medical University中国医科大学附属盛京医院ShenyangHospital page
  44. Study siteSichuan Provincial People's Hospital四川省人民医院ChengduHospital page
  45. Study siteSun Yat-sen Memorial Hospital中山大学孙逸仙纪念医院GuangzhouHospital page
  46. Study siteTaizhou Hospital, Wenzhou Medical University温州医科大学附属台州医院TaizhouHospital page
  47. Study siteTianjin Medical University Cancer Institute & Hospital天津医科大学肿瘤医院TianjinHospital page
  48. Study siteUnion Hospital华中科技大学同济医学院附属协和医院WuhanHospital page
  49. Study siteWeifang People's Hospital潍坊市人民医院WeifangHospital page
  50. Study siteXiangya Hospital中南大学湘雅医院ChangshaHospital page
  51. Study siteYantai Yuhuangding Hospital烟台毓璜顶医院YantaiHospital page
  52. Study siteZhongnan Hospital of Wuhan University武汉大学中南医院WuhanHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07043725, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 7

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (7 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Histologically or cytologically confirmed HER2-positive invasive breast cancer;

    Inclusion criterion 3

  3. Clinical stage at diagnosis: T2-4 with any N, M0, or any T with N1-3, M0;

    Inclusion criterion 5

  4. Adverse reactions from prior treatment not recovered to CTCAE v5.0 grade ≤1;

    Exclusion criterion 7

    Prior excisional biopsy of primary tumor and/or axillary lymph nodes or sentinel lymph node biopsy before study treatment;

    Exclusion criterion 17

  5. Eastern Cooperative Oncology Group performance status (ECOG PS) score: 0-1; expected survival >6 months;

    Inclusion criterion 2

  6. Other malignancies within 5 years or currently;

    Exclusion criterion 6

  7. Must agree to use contraception during the study and for 6 months after study completion; female patients must have a negative serum pregnancy test within 7 days before enrollment and must not be lactating; male subjects must agree to use contraception during the study and for 6 months after study completion

    Inclusion criterion 8

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: blood tests: counts, liver and kidney function; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07043725, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Voluntarily participate in this study, sign the informed consent form, and have good compliance;
  • Eastern Cooperative Oncology Group performance status (ECOG PS) score: 0-1; expected survival >6 months;
  • Histologically or cytologically confirmed HER2-positive invasive breast cancer;
  • Hormone receptor (HR) status confirmed;
  • Clinical stage at diagnosis: T2-4 with any N, M0, or any T with N1-3, M0;
  • Agree to undergo breast cancer resection if meeting surgical criteria after neoadjuvant therapy;
  • Major organ function is adequate, meeting specific criteria;
  • Must agree to use contraception during the study and for 6 months after study completion; female patients must have a negative serum pregnancy test within 7 days before enrollment and must not be lactating; male subjects must agree to use contraception during the study and for 6 months after study completion

Exclusion Criteria:

  • Stage IV metastatic breast cancer or other cases judged by the investigator as unsuitable for radical surgical resection after neoadjuvant therapy;
  • Bilateral breast cancer or inflammatory breast cancer;
  • History of invasive breast cancer or ductal carcinoma in situ;
  • Prior anti-tumor therapy for breast cancer, including chemotherapy, endocrine therapy, targeted therapy, radiotherapy, surgery, etc.;
  • Comorbidities and medical history:
  • Other malignancies within 5 years or currently;
  • Adverse reactions from prior treatment not recovered to CTCAE v5.0 grade ≤1;
  • Major surgery, significant traumatic injury within 4 weeks before first dose, or anticipated major surgery during the study, or unhealed wounds/fractures;
  • Conditions affecting intravenous injection or blood sampling;
  • Congenital bleeding or coagulation disorders, or bleeding/coagulation disorders within 28 days before study treatment, or use of aspirin >325 mg/day (maximum antiplatelet dose), dipyridamole, ticlopidine, clopidogrel, or cilostazol within 7 days before study treatment;
  • Arterial/deep venous thrombotic events within 6 months before first dose, e.g., cerebrovascular accident, deep vein thrombosis, pulmonary embolism;
  • Poorly controlled blood pressure (systolic ≥150 mmHg or diastolic ≥100 mmHg);
  • Significant cardiovascular disease, including;
  • Uncontrolled ≥CTCAE grade 2 infection within 14 days before study treatment;
  • History of interstitial lung disease/pneumonitis (non-infectious) requiring steroid treatment, current interstitial lung disease/pneumonitis, or suspected interstitial lung disease/pneumonitis on screening imaging that cannot be ruled out;
  • Tumor-related symptoms and treatment:
  • Prior excisional biopsy of primary tumor and/or axillary lymph nodes or sentinel lymph node biopsy before study treatment;
  • Surgery, chemotherapy, radiotherapy, or other anti-tumor therapy within 3 weeks before study treatment (washout period calculated from last treatment);
  • Prior taxane or carboplatin therapy for any malignancy;
  • Treatment with National Medical Products Administration-approved traditional Chinese medicine with clear anti-tumor indications within 2 weeks before study treatment.
  • Study treatment-related:
  • Severe hypersensitivity to monoclonal antibodies;
  • Uncontrolled active autoimmune disease within 2 weeks before study treatment;
  • Allergy to any study drug or its components/excipients;
  • Live vaccination within 28 days before study treatment, including measles, mumps, rubella, varicella, yellow fever, seasonal flu, Influenza A virus subtype (H1N1) flu, rabies, Bacille Calmette-Guerin vaccine (BCG), and typhoid vaccines.
  • Any condition judged by the investigator to jeopardize subject safety or study completion.

Quoted from ClinicalTrials.gov, NCT07043725, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07043725, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07043725